|AD-Genetics - Alzheimer's Disease Genetics - Detecting Susceptibility Genes for Late-Onset Alzheimer's disease||The aim of this research is to build a better understanding of the causes of AD and in so doing, provide a platform for the development of targeted treatments and preventions. The study team will be recruiting three groups of people: people with early onset Alzheimer’s disease who developed memory problems before aged 65, people with late onset Alzheimer’s disease, and people with no memory problems who will act as control participants. This will help to identify environmental, biological and genetic factors that influence the progression of Alzheimer’s disease and other neurodegenerative disorders.|
|Adjustment to Progressive Multiple Sclerosis||
Multiple sclerosis (MS) is an incurable, chronic disease of the central nervous system.
The aim of this study is to explore the dynamic processes involved in adjusting to primary progressive (PP) and secondary progressive (SP) Multiple Sclerosis (MS).
The study team are looking to conduct a series of qualitative interviews with people with progressive MS as well as interviews with their family members and health care professionals, in order to advance their understanding.
The theoretical model of adjustment to PP and SP MS will be used to inform future interventions for assisting adjustment to progressive MS.
|PD Pain - The Parkinson's Pain Study||The primary aim of this study is to increase the understanding of pain in Parkinson's Disease (PD), and identify the biomarkers of pain. Biomarkers are small changes in the body that can help with diagnosis, tracking and explaining the disease mechanism. It is hoped that these biomarkers will explain why some patients develop pain and help direct treatment. This study will run alongside two separate studies: the Proband study, and the Oxford Monument Discovery Study. These are two of the world’s largest ever in-depth studies into people with PD. Between them, they are aiming to recruit almost 4000 patients with PD from centres around the UK between 2012 and 2017. All patients in these studies will have had detailed assessments of their PD symptoms, as well as having blood samples taken to identify biomarkers. There will be an additional brief 20-minute assessment of pain at one of these appointments.|
|LonDownS - The London Down Syndrome Consortium: An Integrated Study of Cognition and Risk for Alzheimer's Disease in Down Syndrome||Down Syndrome (DS) occurs due to the presence of three copies of chromosome 21, and is the most common genetic cause of intellectual disability. All individuals with DS have Alzheimer's Disease neuropathology in their brains after the age of 30, yielding a much greater risk for developing the clinical signs of AD compared to the general population. Not all individuals with DS however develop the clinical symptoms of AD. This may be due to differences in their genetic, biological, cognitive or socio-economic profiles, although the contributions of these causes that account for this variation are currently unknown. The proposed study will investigate these variations and their developmental origins. The study team will recruit individual with DS who fit into one of two age groups: adults aged 16 years and older and infants aged 6-60 months. A variety of tests will be performed on the participant's cognitive abilities.|